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KESELAMATAN DAN KECEKAPAN LOSARTAN (50MG) KEPADA 
PESAKIT EUVOLEMIC TEKANAN DARAH TINGGI SELEPAS DIALISIS: 
SINGLE BLIND PERCUBAAN KAWALAN RAWAK 
ABSTRAK 
Pesakit buah pinggang peringkat akhir (ESRD) memerlukan terapi 
penggantian cecair sepanjang hayat atau pemindahan buah pinggang. Hampir 60-
90% pesakit hemodialisis adalah hipertensi. Kajian ini bertujuan untuk membuktikan 
patofisiologi hipertensi dalam kalangan pesakit hemodialisis menyimpulkan bahawa 
90% kes disebabkan oleh lebihan natrium dan isipadu (bergantung kepada isi padu), 
manakala majoriti kes selebihnya mempunyai aktiviti renin (renin dependent), yang 
membawa kepada renin tekan darah tinggi yang bergantung kepada renin. Oleh 
sebab terdapat perubahan isipadu pemalar semasa rawatan dialisis, kemungkinan 
besar pengaktifan sistem renin angiotensin aldosterone (RAAS) berlaku semasa 
dialisis. Pengaktifan RAAS akan menyebabkan vasoconstriction arteri dan kenaikan 
tekanan darah walaupun tahap penghidratan pesakit adalah normal. Oleh itu, di akhir 
sesi dialisis, pesakit akan memperoleh kadar normal cecair di dalam badan walaupun 
masih hipertensi. Monitor komposisi badan (BCM) membantu menganggarkan tahap 
penghidratan pesakit dan berat kering dengan tepat. Memandangkan kepentingan 
sistem RAAS, satu kajian telah dirancang untuk menilai keselamatan dan 
keberkesanan losartan 50 mg (dos losartan yang disyorkan oleh Garis Panduan 
Klinikal K/DOQI) untuk mengurangkan tekanan darah dalam kalangan pesakit 
hipertensi euvolemik pasca dialisis dan memerhatikan kelangsungan hidup mereka 
Trend. Percubaan pelbagai pusat, prospektif, rawak, single-blind dilakukan untuk 
menilai kesan kehilangan 50 mg setiap hari (EOD) sekali sehari (OM) dalam 
xviii 
 
kalangan pesakit hipertensi euvolemik selepas dialisis. Penilaian euvolemik pasca 
dialisis dilakukan oleh monitor komposisi badan (BCM). Covariate Adaptive 
Randomization digunakan oleh peserta ke atas lengan standard atau tangan 
intervensi, dan digunakan selama dua belas bulan. Ujian tekanan darah di peringkat 
awal, intra dan pasca-dialisis (BP) direkodkan, dan sebarang kesan buruk disahkan 
menggunakan skala Naranjo. Trend survival dianalisis menggunakan analisis 
Kaplan-Meier, dan ujian statistik Wilcoxon dilakukan untuk memerhatikan 
perbezaan tekanan darah dari awal hingga 12 bulan menggunakan SPSS versi 20. 
Daripada 229 pesakit yang dianalisis melalui monitor komposisi badan, 96 pesakit 
(41.9 %) dikenalpasti sebagai hipertensi euvolemik post-dialisis. Sampel akhir 88 
pesakit (40.1%) telah dipilih secara rawak kepada kumpulan standard dan intervensi. 
Sejumlah 21 pesakit  (47.8%) ialah lelaki dan 23 pesakit (52.2%) ialah perempuan 
telah dipilih secara rawak kepada lengan standard, berbanding 24 pesakit (54.5%) 
lelaki dan 20 pesakit (45.5%) wanita kepada lengan intervensi. Selepas susulan 
systolic pra-dialisis selama 12 bulan dan diastolic, diastolic intradialisis dan diastolic 
tekanan darah berkurangan dari garis dasar dalam kalangan pesakit-pesakit 
intervensin. Walau bagaimanapun, penurunan tekanan darah sistolic pra-dialisis yang 
ketara selepas 12 bulan susulan hanya dilihat untuk pesakit lengan standard. 
Sebanyak enam kematian dilaporkan di kalangan pesakit lengan standard berbanding 
2 kematian di kalangan lengan intervensi. Antara lengan intervensi, dua kes 
hyperkalemia dilaporkan telah mengakibatkan mereka terkeluar dari kumpulan 
intervensi. Bukan sahaja penggunaan Losartan 50 mg mencapai penurunan tekanan 
darah yang signifikan di kalangan pesakit hipertensi euvolemik pasca dialisis, tetapi 
pesakit-pesakit ini juga mempunyai kadar kematian yang lebih rendah. Selain itu, 
losartan 50mg dapat diterima dengan baik di kalangan peserta kajian 
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SAFETY AND EFFICACY OF LOSARTAN (50 MG) IN POST DIALYSIS 
EUVOLEMIC HYPERTENSIVE PATIENTS: A SINGLE-BLIND 
RANDOMIZED CONTROL TRIAL  
ABSTRACT 
Patients with End Stage Renal Disease (ESRD) require lifelong fluid 
replacement therapy or renal transplant. Almost 60-90 % haemodialysis patients are 
hypertensive. Studies aimed at elucidating the pathophysiology of hypertension 
among haemodialysis patients concluded that 90% cases resulted from sodium and 
volume overload (volume-dependent), while the majority of the remaining cases 
have elevated renin activity (renin dependent), leading to renin dependent high blood 
pressure. Since there is a constant volume variation during dialysis session, there is a 
strong possibility for activation of Renin Angiotensin Aldosterone System (RAAS) 
during dialysis that causes high blood pressure even if they are post dialysis 
euvolemic. Keeping in view the importance of RAAS system, current study was 
designed to assess the safety and effectiveness of losartan 50 mg (losartan dose 
recommended by K/DOQI Clinical Practice Guidelines) in reducing blood pressure 
among post-dialysis euvolemic hypertensive patients and observing their survival 
trends. A single centre, prospective, randomised, single-blind trial was conducted to 
assess the effect of losartan 50mg every other day (EOD), once a morning (OM) 
among post-dialysis euvolemic hypertensive patients. Post-dialysis euvolemic 
assessment was done by a Body Composition Monitor (BCM). Covariate Adaptive 
Randomization was used for allocation of participants to the standard or intervention 
arm, and these participants were followed up for twelve months. Pre-, intra- and 
post-dialysis session blood-pressure (BP) measurements were recorded, and any 
xx 
 
adverse events were confirmed using Naranjo scale. Survival trends were analysed 
using Kaplan-Meier analysis, and a Wilcoxon statistical test was performed to note 
the difference in blood pressure from baseline up to 12 months using SPSS version 
20. Of the total 229 patients analysed via a body composition monitor, 96 (41.9%) 
were identified as post-dialysis euvolemic hypertensive. Final samples of 88 (40.1%) 
patients were randomized into standard and intervention arms. A total of 21 (47.8%) 
male and 23 (52.2%) females were randomized to the standard arm, compared to 24 
(54.5%) male and 20 (45.5%) females to the intervention arm. After follow-up of 12 
months' pre-dialysis systolic (Cohen’s d 0.94, p <0.001) and diastolic (Cohen’s d 
0.45, p 0.01), intradialysis diastolic (Cohen’s d 0.34, p 0.02), post-dialysis systolic 
(Cohen’s d 1.19, <0.001) and diastolic (Cohen’s d 0.95, p <0.001) blood pressure 
was reduced from the baseline among intervention-arm patients. However, a 
significant decline in pre-dialysis systolic blood pressure (Cohen‘s d 0.54, p 0.003) 
after 12 months of follow-up was only observed for standard-arm patients. A total of 
six deaths were reported among standard-arm patients compared to 2 deaths among 
the intervention arm. Among the intervention arm, two confirmed cesses of 
Hyperkalemia were reported that resulted in their drop out. Not only did use of 
Losartan 50 mg achieve an overall significant decline in blood pressure among post-
dialysis euvolemic hypertensive patients, but lower mortality rates were also 
observed. Apart from 2 hyperkalemia cases among intervention arm patients, 
losartan 50mg was well tolerated. 
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CHAPTER 1 
INTRODUCTION 
1.1 Losartan  
Losartan was the first approved by FDA by 1995 as an antihypertensive agent and 
was scheduled for generic release in 2010 [1]. Although many benefits of losartan 
represents a class effect of ARB however losartan has pharmacokinetic and 
pharmacodynamic characteristics and effects that are unique and are not classes 
effects. Benefits of losartan include decreasing proteinuria, slowing the progression 
of diabetic nephropathy, controlling hypertension and decreasing risk of stroke in 
patients with left ventricular hypertrophy [1]. 
Losartan is a non peptide molecule that is a competitive antagonist with selective 
binding to AT1 receptor. Losartan has an oral bioavailability of 33% and has 
significant first pass metabolism using the cytochrome P450. The metabolites appear 
to be a reversible, non competitive inhibitor of the AT1 receptor. Elimination of 
losartan is approximately 40% in urine and 60% in faeces. Losartan and its 
metabolites are highly protein bound, mainly to albumin, but other plasma proteins 
bind them leaving only 1.3% and 0.2% free respectively. The half life of losartan is 2 
hours with the terminal half life of metabolites being longer at 6-9 hours [1]. 
Losartan has FDA approval for the treatment of hypertension either alone or in 
combination with other antihypertensive including diuretics [1].  
The concentration of angiotensin type II receptor (ATII) is about 1,000 times higher 
in the kidney than in the circulation. All the key elements of the RAS system have 
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been demonstrated with in various portions of the kidney and its action have shown 
both paracrine and autocrine regulation. The angiotensin type I receptor (AT1) have 
been detected in almost all parts of nephron [2]. The activation of the AT1 receptor 
leads to up regulation of angiotensinogen, renin and angiotensin converting enzyme 
(ACE). Thus losartan by blocking the AT1 receptor leads to decreased intra renal 
ATII by blocking this up regulation [3]. AII causes the concentration of mesangial 
cells leading to decrease in GFR which can be blocked by losartan. However the 
overall effect of losartan on GFR can be variable, depending on the blood pressure is 
within this range, losartan is associated with an increase GFR .  However, with low 
blood pressure, it may be associated with decrease, increased or unchanged GFR [4].  
One of the unique effects of losartan compared to other AT1 receptor blockers is to 
reduce proximal tubular reabsorption of uric acid that increases uric acid excretion 
and decreases serum uric acid concentration [1]. The changes in uric acid levels have 
been variable in studies where losartan is used as antihypertensive [5, 6]. Reduction 
of proteinuria is associated with stabilization of renal failure and slows its 
progression. This is common in both diabetic and non diabetic nephropathy and is 
both dependent and independent of blood pressure lowering [7].  Losartan have 
shown to decrease proteinuria in non diabetic nephropathies [8].  
Blood pressure reduction is associated with renal protection and slowing of 
progression of CKD. Losartan, in combination with other antihypertensive lowers 
blood pressure [9]. ARBs have shown to provide antihypertensive and reno 
protective effects similar to that of ACE inhibitors. The Renoprotection of Optimal 
Antiproteniuric Dose (ROAD) trial demonstrated that titration to maximal anti 
proteinuric effect of benazeril or losartan beyond usual antihypertensive dose did not 
show increased blood pressure reduction but was associated with significant 
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reduction of doubling the serum creatinine by 49% and 50% respectively. The 
combination of ACE inhibitor and ARB has shown to have a significant reduction of 
proteinuria [9, 10]. The combination of angiotensin II receptor blocker and ACE 
inhibitor and ACE inhibitor in a non diabetic renal disease (COOPERATE) study 
was thought to show this benefit; however due to significant questions regarding this 
study, it was later retracted [11]2]. Blockage of RAS has shown improvements on 
survival and hospitalization in heart failure patients. Higher dose of losartan are 
associated with further decrease in blood pressure and with up to 150mg of losartan, 
there is increasing renin levels and circulating AII[12]. The effect of high dose 
versus low dose losartan on clinical outcomes in patients with heart failure was 
studied in a randomized control trial that compared losartan 50mg with losartan 
150mg. With intent to treat analysis, there was no difference in deaths, but there was 
a significant decrease in hospitalization for heart failure with higher dose. Renal 
impairment, hypotension and hyperkalemia were also observed in higher dose group 
[13]. 
Losartan intervention for endpoint reduction (LIFE) trail was conducted among 
9,193 hypertensive patients. The study participants were randomly assigned to 
losartan or atenolol. Doses were increased and hydrochlorthazide along with other 
antihypertensive therapy were added to obtain a target blood pressure of 
<140/90mmHg. Both medications were started with 50mg and titrated to 100mg as 
needed. The primary endpoint was occurrence of cardiovascular death, myocardial 
infarction or stroke and the composite end point was any of these. The study 
demonstrated that losartan was associated with a significant decline in incidence of 
primary composite end point. Sub studies of LIFE study has provided additional 
advantage for example , losartan treated individuals had a significant regression of 
4 
 
LVH hypertrophy [14], decreased left atrial size[15, 16] and decreased BNP [17]. 
Moreover losartan was also associated with decreased platelet aggression and serum 
uric acid [18].  Clinically significant findings were decreased incidence of atrial 
fibrillation and new onset of diabetes[19, 20]. LIFE study has proven losartan to be 
useful to patients with chronic kidney disease [21] 
1.2 End stage renal disease  
End stage renal disease is a condition where GFR levels <15 ml/min/1.73m
2
 which is 
usually accompanied with signs and symptoms of uremia. End stage renal disease 
patients needs initiation of renal replacement therapy either in form of dialysis or 
transplant [22].  
Creatinine is the bi product of protein metabolism. When kidney function diminishes 
and clearance from kidney is reduced, this leads to elevation in serum creatinine , 
urea and uric acid[23]. Patients in stage 4 may also need dialysis based on their 
kidney function and clinical scenario. The main purpose of dialysis is to act as an 
artificial kidney and eliminate nitrogenous products, urea, excessive electrolytes and 
other waste products from blood. In general two type of dialysis are in practice 
1. Haemodialysis  
2. Peritoneal dialysis 
Haemodialysis procedure involves filtration of blood through different filters and 
dialysis solution. Before initiation of haemodialysis, a vascular access is created 
through which a blood is drawn into dialysis machine where it passes through 
membrane filters. Alongside, dialysis solution is pumped on other side of membrane 
filter thereby aiding in ion exchange. In this way, the waste products that are higher 
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in concentration in blood are drawn to the dialysis solution based on concentration 
gradient. Once this exchange happens the dialysis solution containing waste products 
is pumped out of machine and blood is pumped back in body. On average this 
procedure requires 4 hours to complete [24]. However, in peritoneal dialysis (PD) 
instead if making vascular access, a catheter is placed in the peritoneal cavity (PC) 
instead of making vascular access, a catheter is placed in peritoneal cavity. The same 
dialysis solution is used to fill the peritoneal cavity and is removed on a periodic 
basis to eliminate waste products  
1.3 Prevalence of End stage renal disease  
An estimated 2 million people are suffering from ESRD whereas there is a rise in 5-
7% per year new diagnosed cases with ESRD. Taiwan, Japan, Mexico, US and 
Belgium are the highest prevalent countries with ESRD. According to mortality data 
in 2007, ESRD patients in US are on 15 % higher risk of mortality compared to 
Europe and 33% higher risk of mortality compared to Japan on comparable treatment 
modalities [25]. 
US renal data system annual data report more than 660,000 American being treated 
for renal failure. Of 660,000 end stage renal disease patients , 468,000 patients are on 
dialysis and more than 193,000 have a functioning kidney transplant [26]. In 2013 
only, newly reported kidney failure cases occurred in approximately 117,000 
Americans. Of these patients, 57.3% were male and 42.69% were female patients. 
Altogether 44.3% of patient aged between 45 to 64 years. Diabetes (37.4 %) and 
hypertension (25.2%) made up the majority of primary cause for end stage renal 
disease [26].  
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According to Global burden of disease report 2010, chronic kidney disease is ranked 
27
th
 in the list of cases of death in 1990 that rose up to 18
th
 place by 2010. Over 2 
million end stage renal disease patients worldwide receive treatment in form of 
dialysis or kidney transplant. Yet this number only represents 10% of people that 
actually needed treatment to live. In middle income counter, end stage renal disease 
treatment that include dialysis or kidney transplant, creates a financial burden to the 
people who need it. Many people cannot afford it resulting in a death of over 1 
million people annually from untreated kidney failure. 
Europe represents an estimated 13 % of overall ESRD prevalence worldwide. The 
countries with highest prevalence in Europe include Portugal, Germany Cyprus, 
Spain and Italy. In Europe, of 552,000 patients, 575 are treated with haemodialysis, 
5% with peritoneal dialysis whereas 39% are living with kidney transplant. Kidney 
transplant in Europe is the fastest growing ESRD treatment in Europe representing 
an average 3% increase every year [27]. Reports from England suggest that cost 
associated with chronic kidney disease is higher as compared to breast, lung, colon 
and skin cancer combined. Whereas cost associated with ESRD is estimated to be $ 
12 billion by 2020. In Uruguay, annual cost associated with haemodialysis is close to 
$ 23 million representing a total of 30% of overall budget for National resources 
fund for specialized therapies. Finally, china estimated to lose up to $558 billion over 
nest decade due to effects of disability and death related to heart disease and kidney 
failure [28].  
1.4 Prevalence of end stage renal disease in Malaysia 
The prevalence of stage 1 CKD in Malaysia is estimated as 4.16%, stage 2 as 2.05%, 
stage 3 as 2.26% , stage 4 has 0.24% whereas prevalence of end stage renal disease 
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in Malaysia was reported as 0.36% [29] . According to 22 renal registry 2014, 
Malaysia continues to note an increase linear in new patients on dialysis over 10 
years from 3167 cases in 2005 to 6985 cases in 2015 and at least 7055 cases in 2014 
[30]. A steeper linear rise from 13 thousand in 2005 to almost 35 thousand in 2014 
was observed among number of prevalent dialysis patients. New kidney 
transplantation rate decreased by 50 % over last 10 years to about 3 pmp in 2014 
owing to decreasing trend of live related transplantation due to easy availability of 
dialysis treatment  
In 2014, a total of 6107 new haemodialysis cases were reported representing an 
acceptance rate of 203 pmp whereas 948 new peritoneal dialysis cases were reported 
giving an acceptance rate of 31 pmp. The total number of haemodialysis and 
peritoneal dialysis patients increased to 31,497 and 3270 in 2014 thereby giving a 
prevalence rate of 1046 and 109 pmp respectively. Over last 10 years, the male to 
female ratio for incident and prevalent dialysis patients remains the same as about 55 
to 45%. A total of 58% of new dialysis cases were 55 years or older at the onset of 
dialysis. The dialysis treatment rate exceeded 100 per million populations in all states 
of Malaysia by year 2014 (except Sabah) with the lowest rates in Perlis, Kelantan 
and Sabah [30]. 
1.5 Complications associated with end stage renal failure patients on 
haemodialysis  
A normal kidney helps in removal of waste products from human body, maintain 
body fluids, helps regulate hypertension by releasing hormones, produces activated 
form of vitamin D known as calcitrol maintain acid base electrolyte imbalances and 
importantly produces urine. In addition, the kidney is also responsible for production 
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of erythropoietin that plays an important role in red blood cell formation. Once 
kidney function starts to deteriorate, the equilibrium that is maintained by a healthy 
kidney is disturbed that leads to variety of disorders. A summary of common 
occurring complications associated with end stage renal disease are as follows  
1.5.1 Cardiovascular disease as a complication of end stage renal disease 
patients on haemodialysis  
Cardiovascular disease is one of the most frequent complications associated with end 
stage renal disease. Overall, mortality associated with cardiovascular events among 
end stage renal disease accounts for 44% annually [31]. According to national kidney 
foundation task force on cardiovascular events, mortality rates among general 
population when compared to haemodialysis patients with respect to cardiovascular 
events are higher in latter despite stratification for gender, ethnicity or even age 
group. Young dialysis patients report an approximate 500 times higher 
cardiovascular mortality rates compared to their counterparts in general population 
[32]. Herzog et al in their study observes outcomes among 34, 189 haemodialysis 
patients using US renal data base system report poor prognosis among haemodialysis 
patients with acute infarction. The author reports that cardiac related mortality rates 
were 51.8% at 2 years and 70.2% at 5 years [31]. 
It is important to mention that prevalence of cardiovascular events is increasing 
among all patients with CKD, not only with end stage renal disease. The prevalence 
of left ventricular hypertrophy increases as glomerular filtration declines thereby as 
many as 30% of patients reaching end stage renal disease already have clinical 
evidence of ischemic heart disease or heat failure. Moreover, it is important to note 
that patients with reduced glomerular filtration rate are more likely to die of 
cardiovascular event than they are to develop end stage renal disease [33].  
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The relationship between cardiovascular events and end stage renal disease includes 
common pathological links that includes higher prevalence of conventional and non 
conventional factors. Conventional factors to cardiovascular events among 
haemodialysis patients includes hypertension, dyslipidemia, anaemia, electrolyte 
imbalances, acid base and mineral disorders while non conventional factors include  
fluid overload , inflammation and oxidative stress [34]. Increase in parathyroid 
hormone as a result of CKD-BMD increase cardiac mortality and contribute to the 
development of left ventricular hypertrophy since parathyroid receptors are also 
present in heart [35]. Moreover, parathyroid hormone causes artheroscleosis and 
increases vascular tone that leads to hypertension leading to increase risk for 
cardiovascular disease. Malnutrition is also associated with releases of pro-
inflammatory cytokines that aggregates existing inflammation and acceleration of 
arthrosclerosis[36]. Similarly, fluid overload is strongly associated with hypertension 
among end stage renal disease patients and independently influences vascular and 
endothelial function causing arterial stiffness, artheroscleosis and left ventricular 
hypertrophy. 
Interestingly, another possible explanation for high association between both 
diseases includes “reverse causation”. i.e CKD is a risk factor risk factor for CVD 
and vice versa [37]. This association between CKD and CVD is commonly termed as 
“cardio-renal syndrome” and is defines as a “disorder of heart or kidney whereby any 
acute or chronic dysfunction in one organ induces acute or chronic dysfunction of the 
other organ [37]. 
10 
 
1.5.2 Hypertension as complication of end stage renal disease patients on 
haemodialysis 
Hypertension is common among patients with end stage renal disease. The 
prevalence of hypertension among end stage renal disease patients is up to 90% [29]. 
The prevalence of hypertension in pre dialysis stages of CKD depends upon nature of 
underlying renal disease. The prevalence of CKD related hypertension increases 
linearly with decline of kidney function. Pathogenesis of hypertension among 
haemodialysis patients is multilayered and still not completely elucidated however; 
hypervolemic, increased sympathetic activity, renin angiotensin receptor blocker and 
altered endothelial cell function are few of many reasons.  
1.5.2 (a) Increased extracellular volume/volume overload among end stage renal 
disease patients on haemodialysis 
Among haemodialysis patients, an excretory function of kidney is largely replaced 
by haemodialysis. Absorption of salt and water among haemodialysis patients takes 
place in same manner as among normal people however their excretion require 
haemodialysis procedure. Approximately 1-3 litters of extracellular water is gained 
between each dialysis procedure. These constant fluctuations in volume put 
cardiovascular system under pressure and is also responsible for rise in blood 
pressure among haemodialysis patients [38]. 
Thirst is the main drive behind fluid intake that is dependent on osmolality [39] 
where plasma osmolality is determined by sodium concentration. Among 
haemodialysis patients plasma osmolality depends upon dietary salt intake and net 
sodium gained or lost during dialysis. Individuals with normal renal function 
experience a small rise in plasma concentration after high salt diet that draws fluid 
from fluid from intracellular to extracellular space and simultaneously stimulating 
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hypothalamus and pituitary gland resulting in thirst thereby diluting plasma sodium 
back to normal. Sodium excretion from kidney occurs within 1 hour [40]. An exact 
same mechanism is involved among kidney failure patients except that they are 
unable to excrete sodium thereby resulting in plasma sodium to stay longer and 
induce thirst for longer duration of period. All this causes an higher intake of fluids 
resulting in volume overload that induces high blood pressure among haemodialysis 
patients [41]. Thereby limiting salt intake is absolute vital in reducing thirst and 
interdialytic weight gains. 
Over hydration and sodium retention not only plays an important role in volume 
overload but also by non hemodynamic effects on vascular system. Patients those 
begin dialysis with low pre dialyses blood pressure are at greater risk of cardiac 
failure because of vicious cycle (fluid overload leading to problem in removing fluid  
leading to further overload). Prognosis of such patients is poor as fluid removal is 
slow. To further aggregate this scenario, dialysis patients often have diastolic 
dysfunction. In these patients, a small decrease in filling pressure following dialysis 
procedure may result in decreased cardiac output and hypotension [29].  
Estimation of excess volume is dependent upon estimation of dry weight. In 
haemodialysis patients, dry weight is that weight that at the end of dialysis at which 
the patient can remain normotensive until next dialysis despite retention of salt water. 
At dry weight, the extracellular volume is approximately at normal [42] . Incorrect 
assessments of dry weight will either lead to chronic fluid overload or chronic under 
hydration.  The clinical assessment of fluid overload is relatively difficult and it is 
asses on the basis of high blood pressure, cardiovascular complication and physical 
signs of edema in routine clinical setting. Although edema can roughly estimate 
excess extracellular volume but it of limited value in assessing excess intravascular 
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volume. Moreover, several litters of water should be retained before physical signs of 
edema becoming visible [43]. Other techniques in assessing fluid status include 
ultrasonic evaluation of inferior vena cava diameter but it is subjected to inter patient 
and inter operator variability. Biomarkers such as brain natriuretic peptide (BNP) and 
N-terminal pro brain natriuretic peptide (NT-pro BNP) can reflect changes in fluid 
status but both are induced by presence of cardiovascular disease. And are also 
accumulated in CKD patients , rendering these methods inappropriate for evaluation 
of fluid status [44]. Recently, bioimpedance spectroscopy (BIS) has been used for 
assessment for fluid status and dry weight among end stage renal disease patients. 
1.5.2(a)(i) Dry weight among end stage renal disease patients on haemodialysis 
Sinha and agarwal define dry weight as lowest tolerated post dialysis weight 
achieved via gradual change in post dialysis weight at which there are minimal signs 
or symptoms of either hypovolemic or hypervolemia [44]. 
1.5.2(a)(ii) Benefits of probing dry weight among end stage renal disease 
patients on haemodialysis 
Observational studies support the practice of probing dry weight. Vertes et al, 
reported that 35 of 40 patients became normotensive by achieving dry weight [45]. 
Other report from kayikcioglu et al compared the benefits of non pharmacological 
therapy very pharmacologic therapy control of left ventricular mass among HD 
patients[46]. In a case control study, patients who had been treated at one centre with 
salt restriction and dry weight reduction were compared with patients at another 
centre where antihypertensive based therapy was the primary method of managing 
hypertension. The centre using dry weight and salt restriction as a primary strategy 
had lower antihypertensive drugs usage, lower interdialytic weight gain, lower left 
ventricular mass, better diastolic and systolic left ventricular function and fewer 
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episodes of intradialytic hypotension. These observations are important and clinical 
relevance; they suggest that probing for dry weight as opposed to adding more 
antihypertensive drugs perhaps diminishes the risk of cardiac remodelling and 
mitigates LVH and preserves systolic and diastolic left ventricular function. 
Although a case control study cannot asset causation, the results support the use of 
non pharmacological therapy in the management of ESRD patients could be 
beneficial. 
1.5.2(a)(iii) Assessment of dry weight among end stage renal disease patients on 
haemodialysis 
The physical assessment of dry weight is unreliable for example, pedal edema does 
not correlate with dry weight very well. In a case control study, Agarwal et al, found 
that inferior vena cava diameter, blood volume monitoring, plasma volume makers, 
and inflammation markers were not determinants of edema [47]. For the most part, 
the assessment and achievement of dry weight is an iterative process that often 
provokes uncomfortable intradialytic symptoms such as hypotension, dizziness, 
cramps etc. These symptoms often lead to interventions such as cessation of 
ultrafilteration, administration of saline, premature cessation of dialysis, or placing 
the patient in the head-down position. Interestingly, placing the patients in the head 
down position does little to protect the BP and this practice is questionable [48]; 
raising the leg passively without lowering the head can, however, be effective to rise 
ventricular filling pressure [49]. Often , if dry weight is reduced gently either by 
setting the ultrafiltration goal to just a little above the previous achieved post dialysis 
weight either without changing the dialysis time or better still by prolonging the 
dialysis time to allow for slower ultrafilteration with dialysis , dry weight can be 
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successfully achieved. However a body composition monitor using bio impedance 
technology provides an accurate estimation of patient dry weight  
1.5.2(b) Body composition monitor 
Body composition monitor that utilizes bioimpedance spectroscopy is a unique 
approach that is used to assess fluid distribution in both healthy and diseased 
population. This device has been intensively validated against different gold 
standards in general and haemodialysis population [43, 50]. However in the past 
decade, few studies have shown its validation in NDD-CKD population[51, 52] 
Body composition monitoring (BCM) is a painless and non-invasive method that is 
used to determine amount of body fluids and body composition in terms of lean 
tissue mass and fat tissue mass. It not only measures total body water (TBW) but also 
differentiates between intracellular water (ICW) and extracellular water (ECW) [53]. 
TBW is the sum of ECW and ICW. The ECW consist of interstitial water, plasma 
water and transcellular water.  The ICW comprises of water inside cell and these 
cells are protected by membranes [54]. 
A whole body impedance spectroscopy method is used to assess fluid distribution by 
using multi-frequency (5-100 kHz) low amplitude current. At high frequency, current 
passes through the TBW while at low frequency, the current only passes through 
extracellular water as is is unable to penetrate through cell membranes [55, 56]. BIS 
is based on principle that when multi-frequency current is applied through the body, 
every compartment of body offers resistance that is proportional to the TBW and 
electrolytes present in that compartment. Based on these assumptions, the highest 
conductors of electric current are lean tissue due to large amount of water and 
electrolytes and thus offering a very low resistance to current flow. On the contrary, 
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fat and bones offer high resistance to current flow due to low water and electrolytes 
current [57]. 
The value of fluid overload (FO) or over hydration (OH) is defined in term of ECW 
and is expressed in litres [72]. OH is the difference between the amounts of 
extracellular water (ECW) in the tissue that is predicted by using physiological 
models under normal circumstances. Therefore, the OH value obtained from BCM 
can be compared directly with the value for the normal population [56]  
1.5.2(c) Assessment of fluid status using Body composition monitor  
The person under observation lies flat on the back and with hands palms facing 
downwards. A total of four electrodes are attached to one hand (2 electrodes) and one 
foot (2 electrodes) at the ipsilateral side. A cable is attached to both electrodes at 
hand and feet. A patient card having information regarding patient height, weight, 
blood pressure is added into BCM equipment. Measurement is initiated and results 
are displayed within 2 minutes.  All results are stored in patient card. The card is then 
inserted in the laptop and all results are analysed with fluid management tool 
software. 
1.5.2(d) Clinical uses of body composition monitor  
BCM is an important tool for healthcare professional that helps in determine 
individual hydration status and differentiate clearly between ECW and ICW. Due to 
assessment of lean tissue and fat mass, this technique is extensively used by 
nutritionist in clinics as well as weight management centres. With the help of 
appropriate assessment of total body water and blood pressure, this device helps in 
management of hypertension as well as maintenance of fluid status according to 
patient needs. One of the most common uses of BCM is for haemodialysis patients. 
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BCM helps in determining urea distribution volume for the dialysis prescription does 
which is the amount of fluid volume needed to be removed during haemodialysis. 
1.5.2(e) Limitations of body composition monitor  
The assessment of body composition with BIS has been extensively explored in both 
healthy and diseased population over the last decade. Despite easy handling and 
quick interpretation of results, this technique offers some limitation. BIS cannot be 
used among pregnant females, patients with amputations or pacemakers, patients 
with burns or skin infections due to difficulty of placement of electrodes. The result 
of interpretation are less precise is any condition that makes patient susceptible to 
water retention (congestive heart failure and liver cirrhosis) or where water-
electrolyte balance is disturbed. Lastly, the results are also affected with heavy meal, 
intense physical exercise, dehydration and menstrual cycle [57]. 
1.5.3 Renin angiotensin aldosterone system (RAAS) induced hypertension 
among end stage renal disease patients on haemodialysis 
1.5.3(a) Renin angiotensin aldosterone system pathway 
The renin-angiotensin-aldosterone system (RAAS) is a signalling pathway that is 
responsible for regulating the blood pressure. Stimulated by low blood pressure or 
certain nerve impulses (e.g. in stressful situations), the kidneys release an enzyme 
called renin, that triggers a signal transduction pathway. This renin splits the protein 
angiotensinogen, producing angiotensin I that is converted by another enzyme, the 
angiotensin-converting enzyme (ACE), into angiotensin II [58]. 
Angiotensin II not only causes blood vessels to narrow (vasoconstriction), it also 
simultaneously stimulates the secretion of the water-retaining hormone vasopressin 
in the pituitary gland (hypophysis) as well as the release of adrenaline, nor adrenaline 
and aldosterone in the adrenal gland. 
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Adrenaline and noradrenaline enhance vasoconstriction, aldosterone influences the 
filtration function of the kidneys. The kidneys retain more sodium and water in the 
body and excrete more potassium. The vasopressin from the pituitary gland prevents 
the excretion of water without affecting the electrolytes sodium and potassium. In 
this way, the overall volume of blood in the body is increased: more blood is pumped 
through constricted arteries, which increases the pressure exerted on the artery walls 
known as blood pressure.  
 
Figure 1.1: Renin angiotensin aldosterone system pathway [59] 
1.5.3(b) Effect of RAAS system in kidney  
The renin-angiotensin-aldosterone system amends intravascular volume and cellular 
proliferation in the nephron, whereas activation of AT1 receptors in the kidney 
contributes to hypertension through sodium retention. Effects of angiotensin II on 
intrearenal hemodynamic are critical in blood pressure control. Constriction of 
efferent arterioles by angiotensin II reduces renal blood flow and amends glomerular 
filtration by reducing glomerular capillary pressure.  Changes in peritubular pressure 
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promote movement of sodium and fluid from proximal tubules to interstitium and 
systemic circulation through renal vessels. Moreover, angiotensin II reduces 
medullary blood flow and reducing renal intertital blood pressure thereby decreasing 
sodium and water excretion. The RAAS also increases sodium and water 
reabsorption through direct actions on renal transport function. 
Apart from hemodynamic effects, RAAS also promotes other processes in the 
kidney. Angiotensin II maintain production of nephron-toxic reactive oxygen species 
and stimulates cell proliferation and tissue remodelling [60]. Collagen deposition is 
also enhanced through inhibition of proteases, normally functioning to degrade 
abnormal tissue protein [60]. Similarly studies indicates aldosterone has mitogenic 
and profibrotic properties that directly increases production of the profibrotic 
cytokine transforming growth factor β. Aldosterone synthesis is increased in 
experimental renal ablation models that suggest that it has been associated with 
increased renal fibrosis and progressive loss of renal function. It is proposed that 
both aldosterone-induced hypertensive effects as well as direct mitogenic actions 
synergistically act to promote renal damage. 
1.5.3(c) Role of RAAS in kidney injury  
Based on the homeostatic effects of RAAS of kidney, its importance cannot be over 
emphasised. Excessive activation of RAAS cascade promotes and exacerbates 
pathological changes in kidney. Excessive production of angiotensin II and 
aldosterone is associated with progression of kidney damage. Animal models 
suggests that combination of glomerular capillary hypertension, profibrotic effects 
and proteinuria contributes to kidney damage that is associated with RAAS [61] 
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1.5.3(c)(i) Glomerular capillary hypertension  
The basis of any kidney disease is the injury to nephron and loss of functioning units 
that results in hyper-filtration and glomerular capillary hypertension. This adaptive 
change is detrimental over time to renal function. The hyper-filtration state 
associated with glomerular capillary hypertension up regulates expression of RAAS. 
Stimulation of RAAS cascade causes further glomerular injury by rising glomerular 
capillary pressure through angiotensin II driven efferent arteriolar vasoconstriction.  
Experimentally, hyperglycaemia also stimulates angiotensin II production in 
mesangial cells that leads to mesangial matrix expansion, an effect reversed by use of 
losartan [62] 
1.5.3(c)(ii) Profibrotic Effect 
Elevated glomerular capillary pressure may induce glomerulosclerosis, other factors 
may directly induce RAAS cascade that induces kidney injury. Renal fibrosis is also 
associated with pro inflammatory and profibrotic effects of angiotensin II and 
aldosterone.  The RAAS promotes kidney fibrosis through multiple untoward effects 
that include toxic oxygen radical formation, enhanced cellular proliferation and 
collagen deposition in the kidney. 
1.5.3(c)(iii) Proteinuria   
Activation of RAAS exacerbates proteinuria. Glomerular capillary hypertension 
leads to increased glomerular permeability and excessive protein filtration. The 
RAAS may also lead to proteinuria through renal expression. Although proteinuria is 
a biomarker of renal disease however proteinuria itself contributes to renal injury. 
Protein in urine are toxic to tubules and can result in tubulointerstitial inflammation 
and scaring [63]. Literature suggests that reduction of proteinuria is associated with 
nephro-protection [61]. 
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1.5.3(d) Blockage of RAAS in kidney injury  
Blockage of RAAS results in antagonism of renal pro-fibrotic effects and reduces 
proteinuria. Moreover, interpretation in RAAS reduces the progression of renal 
injury in both diabetic and non-diabetic forms of nephropathy. Animal studies have 
demonstrated that inhibition of RAAS is associated with kidney protection. 
However, another aspect of antagonism effect of RAAS in these animal studies is 
also related to better blood pressure control [64]. Literature suggests that reno-
protection afforded by inhibition of RAAS is blood pressure dependent. Whereby 
using radiotelemetry to measure blood pressure continuously, excellent correlation 
between histological renal damage and blood pressure was demonstrated in rats when 
treated with RAAS inhibitors and untreated control [64] 
1.5.3(e) Over activity of RAAS among hypertensive end stage renal disease 
patients on haemodialysis  
Plasma renin levels are twice as higher in hypertensive haemodialysis patients 
compared to normotensive patients [65]. Similarly higher plasma angiotensin II level 
are also observed in chronic kidney failure [66]. Patients with higher plasma renin 
and angiotensin II levels prior to haemolysis procedure have been associated with 
rise in blood pressure. With dialysis, despite removing excess volume that 
contributes to volume dependent hypertension, Plasma renin levels tend to rise 
higher with minor changes in blood pressure.  Saralasin (partial angiotensin II 
receptor agonist) lowered pre-dialysis blood pressure and to an extent post dialysis 
blood pressure thereby demonstrating interaction in individuals between level of 
angiotensin II and volume dependent high blood pressure [67]. Moreover, Textor et 
al, measuring pre and post dialysis blood pressure with response to plasma renin and 
blood pressure identifies and classify patients based on responses to saralasin as 
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volume dependent hypertensive patients and renin dependent hypertension. The latter 
population of patients responded to reduction in blood pressure with infusion of 
saralasin post dialysis whereas no or non significant effect was observed among 
volume dependent hypertensive patients despite high levels of plasma renin or 
angiotensin II levels [68].  
Perhaps one of the most vivid explanation of increased RAAS was observed among 
hypertensive end stage renal disease patients is observed in anephric patients where 
both kidney are removed. As Plasma renin levels are very low among these patients 
as both kidney are removed, their blood pressure is entirely volume dependent and is 
sensitive to volume changes moreover, introduction of sarasalin to these patients 
have no change in blood pressure. In addition, anephric patients require considerable 
amount of blood volume in order to maintain blood pressure at the same level as 
dialysis patients with intact kidneys [38]. In past, bilateral nephrectomy was 
performed in patients with high level of renin however with greater understanding of 
mechanism of blood pressure in renin dependent individuals, bilateral nephrectomy 
was abandoned as drugs that block RAAS activity were effective in controlling blood 
pressure. 
1.5.4 Increased sympathetic activity associated hypertension among end stage 
renal disease patients on haemodialysis 
Sympathetic activity induced vascular resistance and hypertension is common among 
end stage renal disease. Studies indicate that an increased sympathetic activity is 
observed among chronic haemodialysis patients [69]. In addition, sympathetic 
activity was found to be normal among haemodialysis patients with bilateral 
nephrectomy, leading to hypothesis of sympathetic activity is related to neurogenic 
signal carried by renal afferents arising in the failing kidney [70]. Patients with 
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chronic kidney disease  and renin dependent hypertension, sympathetic over activity 
were normalized by chronic angiotensin converting enzyme inhibitor but not by 
calcium channel blockage, implicating a central neural action of angiotensin II. Other 
factors that may contribute towards increased sympathetic activity include oxidative 
stress, obesity , chronic inflammation, nocturnal hypoxia and elevated levels of 
asymmetric di-methyl-arginine (ADMA) [71]. 
1.5.5 Parathyroid hormone associated hypertension among end stage renal 
disease patients on haemodialysis 
Intracellular calcium levels induced by parathyroid hormone are associated with 
hypertension among end stage renal disease. Entry of calcium in smooth muscles 
cells of blood vessels leads to vasoconstriction thereby leading o hypertension. 
Correction of hyperparathyroidism by either vitamin D administration or 
parathyroidectomy in chronic dialysis patients have resulted in low blood pressure 
[72]. 
1.5.6 Reduced production of prostaglandins/ bradykinins associated 
hypertension among end stage renal disease patients on haemodialysis 
Kidney produces several vasodilating chemicals including kinins, prostaglandins 
antihypertensive neural renomedullary lipids. Fluctuations in production of these 
chemicals lead to hypertension among haemodialysis patients. Decreased levels of 
prostaglandin E2 (PGE2) is observed in hypertensive ESRD patients whereas a 
negative correlation is observed between prostacyclin metabolite 6-keto-PgF1α and 
blood pressure among end stage renal disease patients [29] 
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1.5.7 Management of hypertension among haemodialysis patients  
 
The management of hypertension in dialysis patients is frequently challenging and 
requires the knowledge of pharmacokinetics and pharmacodynamic properties of all 
the agents used. Life style modification is the first and integral part of management 
of hypertension among CKD patients. The importance of salt restriction cannot be 
over emphasised. Achievement of dry weight and reduction of extracellular fluid 
should not be neglected.  
In case of lifestyle modifications are not successful, antihypertensive therapy should 
be initiated. The first line of antihypertensive therapeutic agents recommended by 
NKF KDOQI guidelines are ACE inhibitors or ARBs. The latter reduces LVH in 
haemodialysis patients and may be more potent than ACE inhibitors [73-75]. 
Calcium channel blockers and alpha anti-adrenergic drugs should be an integral part 
of management of hypertension to achieve control if necessary.  In most several 
forms of hypertension, multiple antihypertensive therapies are required. If full dose 
of one agent are ineffective, a second or a third drug should be added. If blood 
pressure is not controlled with dialyses and three antihypertensive agents of different 
classes, patient should be evaluated for a potential secondary cause[76] .  
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Figure 1.2 : Algorithmic approach to the management of hypertension among 
haemodialysis patients [76] 
 
 
 
Life style modification 
Achieve dry weight 
BP goal 
>140/90mmHg 
Chose pharmacotherapy 
Hypertension without compelling 
indication 
Hypertension with compelling 
indication 
Stage I hypertension 
BP 140-159/90-99mmHg) 
Start an ARB or ACEI 
Stage  II hypertension 
BP >160/100mmHg 
Start 2 drug combination 
Usually an ACEI or ARB and 
CCB 
 
Not at goal BP 
Add α or β blocker 
Work up secondary causes  
Drugs for the compelling 
indication 
